I. Important Notes
This semi-annual report summary is derived from the full semi-annual report. To fully understand the company's operating results, financial position, and future development plans, investors should read the full semi-annual report on the media designated by the China Securities Regulatory Commission.
All directors attended the board meeting to review this report.
Non-standard Audit Opinion
□ Applicable Not applicable
Profit Distribution Plan or Capital Reserve Conversion Plan Reviewed by the Board
Applicable □ Not applicable
Whether to convert capital reserve into share capital
□ Yes No
The profit distribution plan approved by the Board is: Based on the company's existing total share capital of 201,784,357 shares, excluding 1,370,900 repurchased shares, for a base of 200,413,457 shares, a cash dividend of 3.00 RMB (tax included) per 10 shares will be distributed to all shareholders. No bonus shares will be issued, and no capital reserve will be converted into share capital.
Preferred Stock Profit Distribution Plan Approved by the Board
II. Company Profile
1. Company Information
| Stock Abbreviation | Huisheng Biotech | Stock Code | 300871 |
|---|---|---|---|
| Stock Exchange | Shenzhen Stock Exchange |
| Contact Information | Board Secretary | Securities Affairs Representative |
|---|---|---|
| Name | Wang Qingfeng | Li Xing |
| Tel | 86-027-83235499 | 86-027-83235499 |
| Office Address | No. 1 Zhonghua Road, Wuchang District, Wuhan | No. 1 Zhonghua Road, Wuchang District, Wuhan |
| hvsen@whhsyy.com | hvsen@whhsyy.com |
2. Key Accounting Data and Financial Indicators
Whether the company needs to retroactively adjust or restate previous years' accounting data